permutations and combinations to determine the most efﬁ- cient method of loading, and elution characteristics. RESULTS: Most rapid uptake was noted with prehydrated microspheres in solubilized doxorubicin, and smaller micro- spheres. Loading efﬁciencies (as a function of residual doxorubicin in buffer) varied from 56.4% to 87.7%. Time dependancy data and elution data will be presented. CONCLUSION: Optimal drug loading of SAP with doxo- rubicin is dependant on size, prehydration, and type of doxorubicin. Given the physical properties of SAP, appli- cation as a platform for drug eluting embolotherapeutic may warrant further clinical investigation. 5:36 PM Abstract No. 159 [Cope] CAM/Ethiodol/PVA Chemoembolization of Liver Me- tastases from Colorectal Carcinoma. M.L. Albert, M.V. Kiefer, S.W. Stavropoulos, J.I. Mondschein, A.A. Patel, M.C. Soulen; University of Pennsylvania, Philadelphia, PA. PURPOSE: Colorectal liver metastases have a poor prog- nosis with 1- and 2-year survival of 70% and 35%(median 20 months) with current sequential systemic therapies. We evaluated response and survival after CAM/Ethiodol/PVA chemoembolization. MATERIALS & METHODS: Chemoembolization with cis- platinum, doxorubicin, mitomycin-C, Ethiodol, and PVA was performed at monthly intervals for 1-4 sessions. Imag- ing, clinical and laboratory evaluation was performed before treatment, one month after and then every 3 months. A second cycle of treatment was performed for intrahepatic recurrence. Toxicity was assessed using CTC v.3.0. Re- sponse was evaluated using RECIST, and survival with Kaplan-Meier analysis. RESULTS: 243 procedures(mean 2.4 per subject) were per- formed over 141 treatment cycles on 103 patients. 30 day mortality was 3.9%. 95/141 cycles were evaluable for re- sponse: 2 (2%) PR, 39 (41%) stable, and 54 (57%) progres- sion. Median TTP in the treated liver was 4 mo. Median TTP of disease anywhere was 3 mo. Median survival was 33 mo. from diagnosis of the primary, 27 mo. from diagnosis of liver metastases, and 9 mo. from chemoembolization. Ac- tuarial survivals are summarized in the Table. Survival was signiﬁcantly better when chemoembolization was per- formed following ﬁrst- or second-line systemic therapy than after 3-5th line therapies (p=0.03). There was no difference in survival between patients with or without extrahepatic metastases (p=0.48). CONCLUSION: Chemoembolization provided local control in 43%. Median survival was 27 mo. from diagnosis of liver metastases. Median survival after chemoembolization was 11 mo. when initiated for salvage after 2 lines of systemic therapy. Presence of extrahepatic disease did not adversely impact survival after liver-directed therapy. Survival (months) Primary Dx Mets Dx Chemoembo Prior Systemic Chemotherapy Lines Extrahepatic Disease 0-1 2 3-5 NO Yes Median 33 27 9 12 11 6 11 8 1-Year 94% 85% 36% 44% 39% 13% 43% 30% 2-year 72% 54% 13% 18% 13% 0% 13% 12% 3-year 40% 27% 4% 2% 6% 4-year 23% 13% 0% 5-year 11% 5% 0% p 0.03 0.48 5:48 PM Abstract No. 160 [Cope] Treatment of Metastatic Colorectal Cancer to the Liver with Y90 Microspheres. S.M. Ibrahim 1 , M.F. Mulcahy 2 , A. Riaz 1 , R.J. Lewandowski 1 , R.K. Ryu 1 , K.T. Sato 1 , V. Gates 1 , R. Omary 1 , R. Salem 1,2 ; 1 Northwestern University - Radi- ology, Chicago, IL; 2 Northwestern University - Medicine, Chicago, IL. PURPOSE: To study Y90 radioembolization as a treatment in patients with metastatic colorectal cancer (CRC) tumors to the liver. MATERIALS & METHODS: 105 CRC patients with pro- gressing liver disease on standard of care polychemotherapy therapy underwent radioembolization with Y90. Kaplan-Meier was used to calculate overall survival from ﬁrst treatment. Sub-analyses were performed according to ECOG perfor- mance status (PS), distribution of the lesions, presence of extrahepatic metastases, baseline bilirubin (normal  1.3 mg/ dL) and baseline albumin (normal  3 mg/dL). RESULTS: The median follow-up time was 20.1 months. The overall median survival was 15.2 months (95% CI: 11.6-21.9). The overall median survival for the patients with ECOG PS 0 (n=68) was 25.8 months (95% CI: 19.7-64.3) and 5.23 months (95% CI: 4.1-7.7) for patients with ECOG PS 0 (n=37) (p0.0001). The overall median survival for the patients with solitary liver lesions (n=11) was 23.5 months (95% CI: 17-64.3) and it was 14.4 months (95% CI: 9.6-19.7) for patients with multifocal disease (n=94) (p=0.09). The overall median survival for the patients with- out extrahepatic metastases (n=60) was 21.0 months (95% CI: 14.8-32.0) and 8.7 months (95% CI: 5.8-14.6) for pa- tients with extrahepatic metastases (n=45) (p=0.004). The overall median survival for the patients with normal base- line bilirubin (n=94) was 17 months (95% CI: 13.3-26) and 5.23 months (95% CI: 4.2-14.52) for patients with elevated bilirubin (n=11) (p=0.0001). The overall median survival for the patients with normal baseline albumin (n=68) was 23.5 months (95% CI: 15.4-32.1) and it was 7.5 months (95% CI: 5.4-12.6) for patients with low albumin (n=37) (p0.0001). CONCLUSION: The treatment of liver metastases from a primary CRC using Y90 has favorable survivals when ap- plied to selected cohorts. In particular, elevated bilirubin, low albumin, extrahepatic metastases and ECOG  0 ap- pear to be exquisite indicators of lowered survival beneﬁt. 6:00 PM Abstract No. 161 Utility of Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma as a Bridge to Transplant. D. Kim 1 , C. Frangakis 2 , A. Koteish 3 , K. Hong 1 , J. Geschwind 1 , C. Georgiades 1 ; 1 Johns Hopkins University - Vascular & Interventional Radiology, Baltimore, MD; 2 Johns Hopkins University - School of Public Health, Bal- timore, MD; 3 Johns Hopkins University - Gastroenterology/ Hepatology, Baltimore, MD. PURPOSE: The objective of this study was to establish whether TACE reduces the risk of dropping-off the liver transplant waiting list for patients with cirrhosis and HCC. MATERIALS & METHODS: This was a retrospective co- hort study. A total of 74 patients with cirrhosis and HCC who were placed on the liver transplant list based on Milan S62